Close Menu

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said today that it has signed separate research and service agreements with pharma firm Daiichi Sankyo and French research institute Centre Léon Bérard.

Under the first agreement, HTG will perform work for Daiichi Sankyo in HTG's VERI/O laboratory. The initial project includes the development of a custom assay to detect nearly 3,000 mRNA targets using the HTG EdgeSeq technology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by
Sophia Genetics

This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources. 

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Sponsored by

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Sponsored by

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.